This report highlights survival and the patient's perspective after prolonged venovenous extracorporeal membrane oxygenation (ECMO) for COVID-19-related respiratory failure. A 36-year-old man with COVID-19 presented with fever, anosmia, and hypoxia. After respiratory deterioration necessitating intubation and lung-protective ventilation, he was referred for ECMO. After 3 days of conventional venovenous ECMO, he required multiple creative cannulation configurations. Adequate sedation and recurrent bradycardia were persistent challenges. After 149 consecutive days of ECMO, he recovered native lung function and was weaned from mechanical ventilation. This represents the longest-duration ECMO support in a survivor of COVID-19 yet reported. Necessary strategies included unconventional cannulation and flexible anticoagulation.

中文翻译：

---

针对 COVID-19 进行体外膜氧合 149 天后肺功能恢复。

本报告重点介绍了长期静脉静脉体外膜氧合 (ECMO) 治疗 COVID-19 相关呼吸衰竭后的生存率和患者的观点。一名患有 COVID-19 的 36 岁男性出现发烧、嗅觉丧失和缺氧症状。在呼吸恶化需要插管和肺保护性通气后，他被转诊接受 ECMO。经过 3 天的传统静脉 ECMO 治疗后，他需要多种创意插管配置。充分镇静和反复出现心动过缓是持续存在的挑战。连续 149 天的 ECMO 治疗后，他恢复了自然肺功能，并脱离了机械通气。这是迄今为止报道的对 COVID-19 幸存者持续时间最长的 ECMO 支持。必要的策略包括非常规插管和灵活的抗凝治疗。